121 related articles for article (PubMed ID: 15511233)
1. Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition.
Brinkmeyer S; Eckert R; Ragg H
Eur J Biochem; 2004 Nov; 271(21):4275-83. PubMed ID: 15511233
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Van Deerlin VM; Tollefsen DM
J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
[TBL] [Abstract][Full Text] [Related]
3. The interaction of glycosaminoglycans with heparin cofactor II.
Tollefsen DM
Ann N Y Acad Sci; 1994 Apr; 714():21-31. PubMed ID: 8017769
[TBL] [Abstract][Full Text] [Related]
4. Molecular mapping of the thrombin-heparin cofactor II complex.
Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC
J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227
[TBL] [Abstract][Full Text] [Related]
5. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
Mitchell JW; Church FC
J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753
[TBL] [Abstract][Full Text] [Related]
6. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
Ciaccia AV; Monroe DM; Church FC
J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
[TBL] [Abstract][Full Text] [Related]
7. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
[TBL] [Abstract][Full Text] [Related]
8. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
Verhamme IM; Bock PE; Jackson CM
J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
[TBL] [Abstract][Full Text] [Related]
9. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
[TBL] [Abstract][Full Text] [Related]
10. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Sheehan JP; Tollefsen DM; Sadler JE
J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
[TBL] [Abstract][Full Text] [Related]
11. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
Sutherland JS; Bhakta V; Filion ML; Sheffield WP
Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.
Baglin TP; Carrell RW; Church FC; Esmon CT; Huntington JA
Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11079-84. PubMed ID: 12169660
[TBL] [Abstract][Full Text] [Related]
13. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
Tollefsen DM
Adv Exp Med Biol; 1992; 313():167-76. PubMed ID: 1442260
[TBL] [Abstract][Full Text] [Related]
14. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Blinder MA; Tollefsen DM
J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
Cooper ST; Rezaie AR; Esmon CT; Church FC
Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
[TBL] [Abstract][Full Text] [Related]
16. Serpin-glycosaminoglycan interactions.
Rein CM; Desai UR; Church FC
Methods Enzymol; 2011; 501():105-37. PubMed ID: 22078533
[TBL] [Abstract][Full Text] [Related]
17. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
18. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
[TBL] [Abstract][Full Text] [Related]
19. Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.
Sarilla S; Habib SY; Tollefsen DM; Friedman DB; Arnett DR; Verhamme IM
Anal Biochem; 2010 Nov; 406(2):166-75. PubMed ID: 20670608
[TBL] [Abstract][Full Text] [Related]
20. Isolation of frog and chicken cDNAs encoding heparin cofactor II.
Colwell NS; Tollefsen DM
Thromb Haemost; 1998 Nov; 80(5):784-90. PubMed ID: 9843172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
